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The tricyclic antidepressant compounds are being developed in greater variety as their clinical effectiveness has been more commonly realized. Irvine (3) has suggested the efficiency and utility of studies employing chemically related compounds according to systematic changes in drug molecular structure. The present study was conducted on imipraminet and amitriptylinett (representing molecular change from ring Nitrogen to double-bonded Carbon), and their respective desmethylated analogues, desmethylimipramine § and nortriptyline** (representing terminal demethylation of each of the former compounds).
In addition to looking systematically for differences in clinical efficacy reflecting such serial molecular changes, this study concentrated particularly upon possible differences that such series of compounds might have upon the interpersonal verbal behaviour elicited by a structured interview situation (4) .· Method Sixty newly admitted patients were selected from the incoming population of the Saskatchewan Hospital North Battleford, within the age range of 18-54 years, on the basis of an independent diagnosis by two psychiatrists of an acute primary depressive illness. Twelve patients were randomly assigned to each of the above four drug groups and a separate placebo comparison group, and°P , which has been demonstrated to be sensitive to druginduced improvement in depression (6, 2) , and the Ward Behavior Inventory as developed by the Massachusetts Mental Health Center Project (I). Thirtyone item symptomatic ratings on the Manifest Depression Scale were made independently by the two psychiatrists before and at the end of the four-week treatment', along with ratings of global degree of depression and the global degree of improvement at the end of the period. Interpersonal verbal behaviour and changes induced in it by the various treatments were compared with a method previously described in detail (4, 5): tape recorded interviews were content analysed, with particular attention to the rate of usage of self-referred affect statements and changes of those rates over periods of the interview (reflecting the patient's affective responsiveness to systematic variation in the interviewer's verbal behaviour: selective reinforcement or silence). Interviews were conducted immediately before treatment and again at the end of the four weeks by the psychiatrist who had little other interview contact with the patient during the study.
Results
Mean daily dosages of drugs prescribed for the subjects within the various groups were imipramine 120, desmethylimipramine 110, amitriptyline 125 and nortriptyline 114 mg; none of these dosages significantly differed between drug groups. The placebo group received equivalent dosages of 130 mg. The two psychiatrists' independent ratings were averaged for all measures. The Manifest Depression Scale scores were analysed for initial comparability of the various groups and then for mean difference scores from the beginning to the end of the treatment. As seen in Table I , the groups were initially not significantly different, but the amount of change induced during treatment differed between the drugs studied to a statistically significant degree. Changes in the global improvement noted at the end of treatment also differed significantly between the drug series. The Ward Behavior Inventory, scored for various subscales, did not appear to be sensitive to differential drug-induced changes between drug groups, .nor to be sensitive to comparative differences in the amount of change occurring in the placebo versus the drug groups.
In analysing the verbal behaviour data to look at changes induced by the various treatment conditions in the patients' affective responsiveness to verbal reinforcement over the periods of the structured interview, a mixed design analysis of variance was conducted. Ratio scores were derived from the number of selfreferred affect statements within each of the three interview periods, divided by the total output of statements within each period. Since multiple interaction terms would be the ones to reveal differential changes from one interview to the next, arcsin-transformed ratio scores were used for the analyses of variance. Initial analyses revealed a marked sex difference within the placebo group, pre-to post-treatment, with regard to the changes which occurred in their selfreferred affect responsiveness to reinforcement. For this reason, and to pre- serve proportionality of sex distribution within each treatment group, the last five cases studied were dropped from the total N, leaving eight female and three male cases within each treatment group for further analysis of variance.
In the analyses of variance the change in rates of making self-referred affect statements in response to selective verbal reinforcement by the interviewer in the second of the three periods, is reflected as the Period factor. The Treatment by Period interactions derive from differences between pre-treatment and final interview in that responsiveness to reinforcement. The differences over the four-week study produced by the various drug or placebo assignments, appear as Group X Treatment X Period effects, and reflect the differential degree of change in this responsiveness to reinforcement which has been elicited by the various compounds.
In the analysis of variance comparing the combined four drug groups (44 patients) to the placebo group (11 patients), with Sex treated as a distinct factor, the over-all Period factor is not significant, while the Treatment X Period interaction term is (reflecting a greater average responsiveness to reinforcement after treatment over the entire population of 55 patients); this increased responsiveness to reinforcement is greater for those patients receiving drugs than for the placebo controls, when the error due to the differing male and female placebo subgroup changes is removed, as indicated by the Treatment X Period X Group X Sex interaction term (See Table II active compounds, revealed that both types of molecular change yielded differences on the measure of increased selfreferred affect responsiveness with treatment. The combined imipramine and desmethylimipramine groups showed a significantly greater increase in responsiveness than did those receiving amitriptyline and nortriptyline (F value for T X P X G is 11.2, d.f, 2 and 80, p<.Ol; See Figures 4a and b) ; again, the combined series of imipramine and amitriptyline showed a lesser increase in responsiveness than did those receiving the desmethylated analogues, desmethylimipramine and nortriptyline (F value for T X P X G is 6.36, d.f. 2 and 80, p<.05; See Figures 5a and b) .
It is noteworthy that these differences in the effect of the various molecularstructure changes resemble in direction the differences found with the psychiatric rating measures of improvement over the treatment period. While both these types of difference in clinical effect operate in the same direction, indicating greater treatment response for the imipramine-desmethylimipramine series compared to the amitriptyline-nortriptyline (clinical ratings and affect responsiveness changes, both being significantly greater for the ring Nitrogen series than the double-bonded Carbon analogues), correlations were not found between the pre-to post-treatment difference scores from the quadratic trends of self-referred affect usage over periods and the difference scores from the Manifest Depression Scale, nor between them and Global Improvement.
Discussion and Conclusions
Both the psychiatric rating scales and the measure of interpersonal responsiveness in interview showed differences between the drug-treated and the placebo patients. However, with such small groups of patients under each of the treatment conditions, even in a randomized double-blind design, the observed differences between drugs are to be taken only as suggestive rather than conclusive.
Analysing the data in terms of serial molecular changes through four distinct but analogous compounds, alteration to ring Nitrogen from double-bonded Carbon appears to favour greater clinical response over the four-week treatment period, indicated both by the changes in the psychiatric symptom ratings and in the interview measure; desmethylation appears also to favour the clinical change occurring in terms .of increased interpersonal responsiveness in interview, but does not produce in our data clear direct comparative differences on the psychiatric ratings of symptomatology and improvement.
The changes appearing with active drug treatment in the measure of interpersonal responsiveness are not clear in their clinical implication, since they do not correlate directly with the general symptom-rated improvements. It is nevertheless interesting to be able to measure, on an objective dimension of interpersonal verbal behaviour, differential changes which depend upon varying treatment conditions. Clinical observation often has described the depressive as being unresponsive to interpersonal stimuli and showing an increased verbal responsivity in interview when clinical improvement occurs: the present data indicate that depressives' specific responsiveness to selective reinforcement of self-referred affect statements increases significantly after antidepressant treatment, a finding that may be of interest to those clinicians who frequently treat such patients with a combination of antidepressant drugs and psychotherapeutic methods.
Summary
Imipramine, amitriptyline and their two desmethylated analogues were compared to a placebo and to each other in terms of serial changes in molecular structure over a four-week treatment period in a double-blind design. Twelve acutely depressed patients were randomly assigned to each drug and to the placebo group. Clinical psychiatric ratings and a measure of verbal responsiveness to selective reinforcement in interviews both showed the active drugs to produce greater change than the placebo. Suggestive differences between the drugs favoured the imiprarnine-desmethylimipramine series over the amitriptyline-nortriptyline, while desmethylation also appeared to favour the change with treatment towards increased interpersonal responsiveness.
Resume L'imipramine, l'amitriptyline et leurs deux analogues demethyles ont ete compares a un placebo et l'un avec l'autre sous forme de changements en serie de leur structure moleculaire, durant une periode de traitement de quatre semaines selon la methode a double insu. Douze malades atteints de depression aigue ont ete assignes au hasard a chaque medicament et au groupe recevant Ie placebo. Les cotes de psychiatrie clinique ainsi qu'une certaine mesure de reaction verbale au renforcement selectif lors d'entrevues ont rnontre toutes deux que les medicaments actifs produisaient des changements plus prononces que ne Ie faisait Ie placebo. Les differences accusees entre les medicaments favorisaient la serie de l'imipramine-imipramine demethylee par rapport a I'arnitriptylinenortriptyline tandis que la dernethylation semblait aussi favoriser Ie changement survenu au cours du traitement vers une reaction interpersonnelle.
